Genmab A/S (NASDAQ:GMAB) was the recipient of a significant decrease in short interest during the month of January. As of January 31st, there was short interest totalling 488,000 shares, a decrease of 27.1% from the January 15th total of 669,000 shares. Based on an average daily volume of 251,200 shares, the short-interest ratio is currently 1.9 days. Currently, 0.1% of the shares of the stock are short sold.

Several research firms have weighed in on GMAB. HC Wainwright restated a “buy” rating and set a $25.00 target price on shares of Genmab A/S in a research note on Tuesday. ValuEngine upgraded Genmab A/S from a “sell” rating to a “hold” rating in a research note on Tuesday, December 3rd. Deutsche Bank cut Genmab A/S from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Zacks Investment Research cut Genmab A/S from a “hold” rating to a “sell” rating in a research note on Saturday, January 4th. Finally, SunTrust Banks began coverage on Genmab A/S in a research note on Monday, January 13th. They issued a “buy” rating for the company. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $23.67.

Several institutional investors and hedge funds have recently made changes to their positions in the company. UBS Group AG lifted its stake in shares of Genmab A/S by 11.5% in the 4th quarter. UBS Group AG now owns 5,190 shares of the company’s stock valued at $116,000 after acquiring an additional 537 shares during the last quarter. PNC Financial Services Group Inc. lifted its stake in shares of Genmab A/S by 8.0% in the 4th quarter. PNC Financial Services Group Inc. now owns 10,932 shares of the company’s stock valued at $245,000 after acquiring an additional 810 shares during the last quarter. Comerica Bank lifted its stake in shares of Genmab A/S by 2.5% in the 4th quarter. Comerica Bank now owns 38,449 shares of the company’s stock valued at $893,000 after acquiring an additional 944 shares during the last quarter. Kayne Anderson Rudnick Investment Management LLC lifted its stake in shares of Genmab A/S by 0.9% in the 4th quarter. Kayne Anderson Rudnick Investment Management LLC now owns 127,189 shares of the company’s stock valued at $2,840,000 after acquiring an additional 1,170 shares during the last quarter. Finally, Assetmark Inc. lifted its stake in shares of Genmab A/S by 28.6% in the 4th quarter. Assetmark Inc. now owns 5,301 shares of the company’s stock valued at $118,000 after acquiring an additional 1,180 shares during the last quarter. Institutional investors own 19.80% of the company’s stock.

Shares of GMAB traded up $0.01 during trading hours on Friday, reaching $23.88. The stock had a trading volume of 268,500 shares, compared to its average volume of 274,287. Genmab A/S has a 12 month low of $15.15 and a 12 month high of $24.50. The company has a market cap of $3.05 billion and a PE ratio of 6.33. The company has a debt-to-equity ratio of 0.01, a current ratio of 18.72 and a quick ratio of 18.72. The stock has a 50-day moving average price of $22.83.

Genmab A/S Company Profile

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).

Featured Article: Outstanding Shares, Buying and Selling Stocks

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.